公开(公告)号：EP2953452A1

公开(公告)日：2015-12-16

申请号：EP14705679.0

申请日：2014-02-06

申请人： Regeneron Pharmaceuticals, Inc. ,  Duke University

发明人： HAYNES, Barton ,  KELSOE, Garnett ,  LOWY, Israel ,  MACDONALD, Lynn ,  BARAS, Aris, I. ,  GURER, Cagan ,  MEAGHER, Karolina, A. ,  MCWHIRTER, John ,  MURPHY, Andrew, J. ,  YANCOPOULOS, George, D.

IPC分类号： A01K67/027 ,  A61K39/00 ,  C07K16/00

CPC分类号： C07K16/1045 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/10 ,  C07K16/1018 ,  G01N2500/00

摘要： Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.

公开(公告)号：EP2787075B1

公开(公告)日：2016-11-30

申请号：EP14172420.3

申请日：2002-02-15

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： MURPHY, Andrew J. ,  YANCOPOULOS, George, D. ,  ECONOMIDES, Aris ,  KAROW, Margaret ,  MACDONALD, Lynn ,  STEVENS, Sean ,  VALENZUELA, David

IPC分类号： C12N15/00 ,  C12N15/09 ,  C12N15/63 ,  C12N15/74 ,  C12N5/00 ,  C12N5/02 ,  C12N5/16 ,  C12P21/06 ,  C12P21/04

CPC分类号： C12P21/00 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/28 ,  C07K16/462 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C12N15/67 ,  C12N15/85 ,  C12N15/8509 ,  C12N15/902 ,  C12N15/907 ,  C12N2800/204

公开(公告)号：EP1360287B1

公开(公告)日：2012-09-12

申请号：EP02709544.7

申请日：2002-02-15

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： MURPHY, Andrew, J. ,  YANCOPOULOS, George, D.

IPC分类号： C12N15/00 ,  C12N15/09 ,  C12N15/63 ,  C12N15/74

CPC分类号： C12P21/00 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/28 ,  C07K16/462 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C12N15/67 ,  C12N15/85 ,  C12N15/8509 ,  C12N15/902 ,  C12N15/907 ,  C12N2800/204

摘要： A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

公开(公告)号：EP1563298A2

公开(公告)日：2005-08-17

申请号：EP03742008.0

申请日：2003-06-17

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： MURPHY, Andrew, J. ,  SHANKER, Gopi, Y. ,  YANCOPOULOS, George, D.

IPC分类号： G01N33/53 ,  C12Q1/68 ,  C12N15/00

CPC分类号： C40B30/04 ,  C07K14/685 ,  C07K14/705 ,  C07K14/70535 ,  C07K16/44 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/6845 ,  G01N33/6857

摘要： Methods for identifying a compound capable of modulating activity of a target active domain, by generating a first fusion protein having an anchor component and a variable component, generating a second fusion protein having a docking domain and an active domain, wherein the anchor component and the docking domain are binding partners, then contacting the fusion proteins under conditions in which the anchor component and the docking domain bind, and determining the activity of the target domain.

公开(公告)号：EP0866860B1

公开(公告)日：2004-03-31

申请号：EP96945068.3

申请日：1996-12-13

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： VALENZUELA, David, M. ,  GLASS, David, J. ,  BOWEN, David, C. ,  YANCOPOULOS, George, D.

IPC分类号： C12N15/12 ,  C12N15/16 ,  C12N15/70 ,  C12N15/81 ,  C12N15/85 ,  C12N5/10 ,  C12N1/19 ,  C12N1/21 ,  C12Q1/68 ,  C12P21/02 ,  C07K14/575 ,  C07K16/26 ,  A61K38/22 ,  A61K48/00 ,  G01N33/53

CPC分类号： C07K14/78 ,  A61K38/00 ,  A61K48/00 ,  C07K14/70567 ,  C07K14/70571 ,  C07K14/811 ,  C07K16/38

摘要： The present invention provides for a gene, designated as musk , that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.

公开(公告)号：EP1231934B1

公开(公告)日：2004-03-24

申请号：EP00980561.5

申请日：2000-11-17

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： GLASS, David, J. ,  ROMMEL, Christian ,  BODINE, Sue, C. ,  YANCOPOULOS, George, D.

IPC分类号： A61K38/30 ,  A61K31/00 ,  A61K38/00 ,  C12N5/10 ,  C12Q1/02 ,  A61P3/00 ,  A61P3/08 ,  A61P21/00

CPC分类号： G01N33/5061 ,  A61K38/30 ,  G01N33/5008 ,  G01N33/5041 ,  G01N33/5044

摘要： The present invention provides a method for inhibiting atrophy or causing hypertrophy in muscle cells. It further provides a method for inhibiting skeletal muscle atrophy or causing skeletal muscle hypertrophy in vertebrate animals. It also provides a method of identifying agents that may be method for inhibiting atrophy or causing hypertrophy in muscle cells.

公开(公告)号：EP0915974B1

公开(公告)日：2004-03-17

申请号：EP97937086.3

申请日：1997-08-01

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： DAVIS, Samuel ,  YANCOPOULOS, George, D.

IPC分类号： C12N15/12 ,  C07K14/515 ,  C07K14/71 ,  C07K16/22 ,  C12N15/62 ,  C07K19/00 ,  A61K38/17 ,  A61K38/18 ,  A61K39/395 ,  A61K49/00 ,  A61K51/08

CPC分类号： C12N15/8509 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2227/30 ,  A01K2267/01 ,  A01K2267/03 ,  A01K2267/0331 ,  A01K2267/0375 ,  A01K2267/0381 ,  A61K38/00 ,  C07K14/515 ,  C07K14/71 ,  C07K2319/00 ,  C07K2319/02

摘要： The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.

公开(公告)号：EP1363677A1

公开(公告)日：2003-11-26

申请号：EP02706033.4

申请日：2002-01-28

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： XIA, Yuping ,  RUDGE, John, S. ,  YANCOPOULOS, George, D.

IPC分类号： A61K48/00 ,  A61K38/17 ,  A61K38/18 ,  C12N15/85

CPC分类号： C07K14/71 ,  A61K38/00 ,  C07K2319/00

摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal. Also disclosed are methods of treating diseases in which plasma leakage and/or vascular permeability occurs, for example, inflammatory skin diseases.

公开(公告)号：EP0939809B1

公开(公告)日：2003-03-26

申请号：EP97930162.9

申请日：1997-06-19

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： VALENZUELA, David, M. ,  JONES, Pamela, F. ,  YANCOPOULOS, George, D.

IPC分类号： C12N15/12 ,  C07K14/17 ,  A61K38/18 ,  C07K14/745 ,  C07K16/22

CPC分类号： C07K14/71 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  A61K38/00 ,  C07K14/515 ,  C07K2319/00 ,  C07K2319/02 ,  C12N15/8509

摘要： The present invention provides for an isolated nucleic acid molecule encoding a member of the TIE ligand family. The present invention also provides for an isolated nucleic acid molecule encoding TIE ligand-3 or TIE ligand-4. In addition, the invention provides for a receptor body which specifically binds TIE ligand-3 or TIE ligand-4. The invention also provides an antibody which specifically binds TIE ligand-3 or TIE ligand-4. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.

公开(公告)号：EP0589961A1

公开(公告)日：1994-04-06

申请号：EP92912036.0

申请日：1992-04-23

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： SQUINTO, Stephen, P. ,  GLASS, David ,  ALDRICH, Thomas, H. ,  DiSTEPHANO, Peter ,  STITT, Trevor ,  FURTH, Mark, E. ,  YANCOPOULOS, George, D. ,  MAISONPIERRE, Peter, C. ,  MASIAKOWSKI, Piotr ,  IP, Nancy

IPC分类号： G01N ,  A01K67 ,  C07K7 ,  C07K14 ,  C12N5 ,  C12N9 ,  C12N15 ,  C12P21 ,  C12Q1 ,  G01N33 ,  A61K38

CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K14/71 ,  C07K14/82 ,  C12Q1/00 ,  C12Q1/02 ,  G01N33/50 ,  G01N33/573 ,  G01N33/6872 ,  G01N33/6896 ,  G01N2333/475

摘要： L'invention concerne des systèmes d'analyses qui peuvent être utilisés pour détecter et/ou mesurer l'activité de la neurotrophine et pour identifier des agents ayant une activité semblable à celle de la neurotrophine. L'invention se base, au moins en partie, sur la découverte que le proto-oncogène trkB code un récepteur de la tyrosine kinase qui peut servir de protéine de liaison fonctionnelle pour BDNF et NT-3. L'invention concerne également des procédés diagnostiques et thérapeutiques fondés sur l'interaction entre BDNF et/ou NT-3 et trkB, et pour plusieurs molécules réceptrices d'orphan.

摘要翻译： 本发明提供了可用于检测和/或测量神经营养因子活性并鉴定具有与神经营养因子相似活性的药剂的测定系统。 本发明至少部分基于发现trkB原癌基因编码可用作BDNF和NT-3的功能性结合蛋白的酪氨酸激酶受体。 本发明还涉及基于BDNF和/或NT-3和trkB之间以及几种孤儿受体分子之间相互作用的诊断和治疗方法。